Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys

Vaccine

Volumn 30, Issue 5, 2012, Pages 846-852

  Chabot, Donald J ^a   Joyce, Joseph ^b   Caulfield, Michael ^b,d   Cook, James ^b   Hepler, Robert ^b   Wang, Su ^b   Vietri, Nicholas J ^a   Ruthel, Gordon ^a   Shoop, Wesley ^b   Pitt, Louise ^a   Leffel, Elizabeth ^a   Ribot, Wilson ^a   Friedlander, Arthur M ^a,c  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Anthrax; Capsule; Conjugate; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL CAPSULE VACCINE; BACTERIAL VACCINE; CAPSULE OUTER MEMBRANE PROTEIN COMPLEX CONJUGATE VACCINE; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN COMPLEX; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BACTERIAL SPORE; CELL ADHESION; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MONKEY; EXPERIMENTAL RABBIT; FEMALE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SPECIES DIFFERENCE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MACACA MULATTA; MACROPHAGES; MALE; NEISSERIA MENINGITIDIS; OPSONIN PROTEINS; PHAGOCYTOSIS; RABBITS; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 84855455237     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.010     Document Type: Article

References (49)

1. Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287(17):2236-2252.
2. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7(6):933-944.
3. Friedlander A.M., Pittman P.R., Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999, 282(22):2104-2106.
4. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 1992, 60(2):662-668.
5. Brachman P.S., Friedlander A.M., Grabenstein J.D. Anthrax vaccine. Vaccines 2008, 111-126. Saunders, Elsiever, Burlington, MA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
6. Friedlander A.M., Welkos S.L., Ivins B.E. Anthrax vaccines. Current Topics on Microbiology and Immunology 2002, 33-60. Springer Verlag, New York. T.M. Koehler (Ed.).
7. Little S.F., Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986, 52(2):509-512.
8. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986, 52(2):356-363.
9. Brossier F., Levy M., Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002, 70:661-664.
10. 2-dependent expression of the genetic region for encapsulation from Bacillus anthracis. Mol Microbiol 1988, 2(3):371-376.
11. Makino S., Uchida I., Terakado N., Sasakawa C., Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 1989, 171(2):722-730.
12. Green B.D., Battisti L., Koehler T.M., Thorne C.B., Ivins B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 1985, 49(2):291-297.
13. Uchida I., Sekizaki T., Hashimoto K., Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol 1985, 131(2):363-367.
14. Candela T., Mock M., Fouet A. CapE, a 47-amino-acid peptide, is necessary for Bacillus anthracis polyglutamate capsule synthesis. J Bacteriol 2005, 187(22):7765-7772.
15. Uchida I., Makino S., Sasakawa C., Yoshikawa M., Sugimoto C., Terakado N. Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol Microbiol 1993, 9(3):487-496.
16. Candela T., Fouet A. Bacillus anthracis CapD, belonging to the gamma-glutamyltranspeptidase family, is required for the covalent anchoring of capsule to peptidoglycan. Mol Microbiol 2005, 57(3):717-726.
17. Richter S., Anderson V.J., Garufi G., Lu L., Budzik J.M., Joachimiak A., et al. Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin. Mol Microbiol 2009, 71(2):404-420.
18. Scorpio A., Chabot D.J., Day W.A., O'Brien D.K., Vietri N.J., Itoh Y., et al. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother 2007, 51(1):215-222.
19. Meynell E., Meynell G.G. The roles of serum and carbon dioxide in capsule formation by Bacillus anthracis. J Gen Microbiol 1964, 34:153-164.
20. Hoffmaster A.R., Koehler T.M. Control of virulence gene expression in Bacillus anthracis. J Appl Microbiol 1999, 87(2):279-281.
21. Uchida I., Makino S., Sekizaki T., Terakado N. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. Mol Microbiol 1997, 23(6):1229-1240.
22. Drysdale M., Bourgogne A., Hilsenbeck S.G., Koehler T.M. AtxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol 2004, 186(2):307-315.
23. Zwartouw H.T., Smith H. Polyglutamic acid from Bacillus anthracis grown in vivo; structure and aggressin activity. Biochem J 1956, 63(3):437-442.
24. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 2004, 23(1):43-47.
25. Shlyakhov E.N., Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994, 12(8):727-730.
26. Wang T.T., Lucas A.H. The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen. Infect Immun 2004, 72(9):5460-5463.
27. Schneerson R., Kubler-Kielb J., Liu T.Y., Dai Z.D., Leppla S.H., Yergey A., et al. Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 2003, 100(15):8945-8950.
28. Wang T.T., Fellows P.F., Leighton T.J., Lucas A.H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol Med Microbiol 2004, 40(3):231-237.
29. Goodman J.W., Nitecki D.E. Studies on the relation of a prior immune response to immunogenicity. Immunology 1967, 13(6):577-583.
30. Lee D.Y., Chun J.H., Ha H.J., Park J., Kim B.S., Oh H.B., et al. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits. FEMS Immunol Med Microbiol 2009, 57(2):165-172.
31. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J. Wang JY A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 2003, 100(19):10925-10930.
32. Joyce J.G., Cook J., Chabot D., Hepler R., Shoop W., Xu Q., et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 2006, 281(8):4831-4843.
33. Kozel T.R., Murphy W.J., Brandt S., Blazar B.R., Lovchik J.A., Thorkildson P., et al. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci USA 2004, 101(14):5042-5047.
34. Kozel T.R., Thorkildson P., Brandt S., Welch W.H., Lovchik J.A., AuCoin D.P., et al. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun 2007, 75(1):152-163.
35. Worsham P.L., Sowers M.R. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can J Microbiol 1999, 45(1):1-8.
36. Caulfield M.J., Shaffer D. A computer program for the evaluation of ELISA data obtained using an automated microtiter plate absorbance reader. J Immunol Methods 1984, 74(2):205-215.
37. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001, 19(32):4768-4773.
38. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998, 16(11-12):1141-1148.
39. National Research Council Guide for the Care and Use of laboratory Animals 1996, Natl. Acad. Press, Washington, DC.
40. Pasteur L (with the collaboration of Mr. Chamberland and Mr. Roux). Summary report of the experiments conducted at Pouilly-le-Fort, near Melun, on the anthrax vaccination (French). Comptes Rendus de l'Academie des Science 1881; 92:1378-83.
41. Tigertt W.D. Anthrax. William Smith Greenfield, M.D., F.R.C.P., Professor Superintendent, the Brown Animal Sanatory Institution (1878-81). Concerning the priority due to him for the production of the first vaccine against anthrax. J Hyg (Lond) 1980, 85(3):415-420.
42. Toussaint H. Method for vaccinating sheep and young dogs (French). C R Hebd Seances Acad Sci 1880, 91:303-304.
43. Stepanov A.V., Marinin L.I., Pomerantsev A.P., Staritsin N.A. Development of novel vaccines against anthrax in man. J Biotechnol 1996, 44(1-3):155-160.
44. The anthrax vaccine: Is it safe? Does it work? 2002, National Academy Press, Washington, DC. L.M. Joellenbeck, L.L. Zwanziger, J.S. Durch, B.L. Strom (Eds.).
45. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006, 24(33-34):5950-5959.
46. Campbell J.D., Clement K.H., Wasserman S.S., Donegan S., Chrisley L., Kotloff K.L., et al. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccine 2007, 3(5):205-211.
47. Pomerantsev A.P., Staritsin N.A., Mockov Y.V., Marinin L.I. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 2007, 15(17-18):1846-1850.
48. Stern E.J., Uhde K.B., Shadomy S.V., Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008, 14(4). [pii: 07-0969].
49. Zaucha G.M., Pitt M.L.M., Estep J., Ivins B.E., Friedlander A.M. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 1998, 122:982-992.